People in the News

People in the News

(Page
1
of
1)

Click Image To Enlarge +

Peter Lucas

Bibby Scientific U.S. hired Peter Lucas as president for the western hemisphere. Before this appointment, Lucas served as North American director of marketing, laboratory solutions at Sartorius. He has also worked for Merck KGaA Millipore.

Molecular Partners hired Lisa Rojkjaer, M.D., as CMO...Knome appointed Gary A. Cohen, J.D., as svp and general counsel and Heidi L. Rehm, Ph.D., to its scientific advisory board...Martin Latterich, Ph.D., is now CSO of BioScale...Pressure BioSciences appointed Vito Mangiardi and Kevin Pollack to its newly configured board of directors.

Click Image To Enlarge +

Donald E. Pogorzelski

Diffinity Genomics appointed Donald E. Pogorzelski to its board of directors. Pogorzelski was previously president of Genzyme Diagnostics prior to its sale to Sekisui Chemical in 2011. Before joining Genzyme, he was regional marketing manager, Boston region (Northeast) of Abbott Laboratories’ diagnostics division.

Damian Marron is now CEO of Cytheris...Trophos appointed Christine Placet as CEO...to-BBB hired Ajay Mistry, Ph.D., as head of business development...Transgenomic appointed John M. McAuliffe as vp of business development, neurology, and Matthew W. Beer as vp of business development, oncology.

Click Image To Enlarge +

Eric Allyn

Diffinity Genomics appointed Eric Allyn to its board of directors. Allyn is an owner of Welch Allyn, where he is now co-chairman of its board. Since starting his career there in 1982, he has held various roles including sales management and marketing communications.

Alnylam Pharmaceuticals appointed Oved Amitay to vp, head of commercial and promoted Akshay Vaishnaw, M.D., Ph.D., to evp and CMO; Jared Gollob, M.D., to vp, clinical research; and Lubomir (Lubo) Nechev, Ph.D., to vp, process sciences...Carolyn Beaver is now vp and CAO of Sequenom...EvaluatePharma named Debbie Paul CEO, Americas...Anavex appointed Robert Chisholm as CFO...Accelr8 Technology hired Lawrence Mehren as president, CEO, and a member of the board of directors.

Click Image To Enlarge +

Nissim Mashiach

Macrocure named Nissim Mashiach as president and CEO. Mashiach has worked in the pharmaceutical industry for 25 years, most recently as general manager at Ethicon, a Johnson & Johnson company. He has also served as president and COO at Omrix Biopharmaceuticals.

MethylGene elected Rodney Lappe, Ph.D., to its board of directors...Antares Pharma appointed Jonathan S. Jaffe, M.D., as vp, clinical development...Gen9 appointed Kevin Munnelly as president and CEO...Cleave Biosciences appointed David Wustrow, Ph.D., as vp, chemistry...Ricerca Biosciences appointed G. Lynn Miesel, Ph.D., as technical director...Cubist Pharmaceuticals named Robert J. Perez president and COO, Michael Tomsicek svp and deputy CFO, and Thomas Rollins svp, program and portfolio management.

Click Image To Enlarge +

Scott A. Siegel, Ph.D.

Scott A. Siegel, Ph.D., has been named COO of Ezose Sciences. Dr. Siegel has worked in the biotechnology and pharmaceutical industries for over 25 years. He joined Ezose in 2009; before that, he was vp, corporate development for Redpoint Bio. He has also worked at Johnson & Johnson.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.3%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.